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Negative correlation between Placental Growth Factor and Endocan-1 in women with preeclampsia 
Correlação negativa entre fator de crescimento placentário e Endocan-1 em mulheres com preeclampsia 
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Abstract 
Objective: To analyse Endocan-1, a biomarker of vascular endothelial related pathologies, and Placental growth 
factor (PlGF), an angiogenic factor and a placental dysfunction marker in patients with pre-eclampsia (PE).  
Methods: Case-control study conducted at São Lucas Hospital. Endocan-1 and PlGF levels were quantified in 
maternal plasma using MagPlexTH-C microspheres system and analysed by ANCOVA adjusted by BMI, gestational 
age and maternal age. To estimate the difference between groups, mean ratio (MR) and 95% confidence interval (CI) 
were calculated. Pearson correlation test was used to establish any association between Endocan-1 and PlGF levels. 
The null hypothesis was rejected when p <0.05. 
Results: The group of patients was composed by normotensive (n=67) and patients with PE (n=50). A negative 
correlation between Endocan-1 and PlGF was noted in the entire group (r= -0,605; p< 0.001); as well as in the PE 
group (r= -0,545; p< 0.001). 
Conclusion: Endocan-1 levels are increased in patients with PE and inversely correlated with PlGF levels. We 
suggest that it is important to analyze angiogenic and pro-inflammatory molecules concomitantly in women with PE to 
better understand the disease pathophysiology. Both molecules are strong competitors as a PE biomarkers and future 
work will examine any mechanisms connecting these factors in PE. 
 
Resumo 
Objetivo: Analisar o Endocan-1, um biomarcador de patologias vasculares endoteliais, e o Fator de crescimento 
placentário (PlGF), um fator angiogênico, marcador de disfunção placentária em pacientes com pré-eclâmpsia (PE). 
Métodos: Estudo caso-controle realizado no Hospital São Lucas. Os níveis de Endocan-1 e PlGF foram 
quantificados no plasma materno usando o sistema de microesferas MagPlexTH-C e analisados por ANCOVA 
ajustados por IMC, idade gestacional e idade materna. Para calcular a diferença entre os grupos, calculou-se a razão 
das médias (MR) e o intervalo de confiança de 95% (CI). O teste de correlação de Pearson foi utilizado para 
estabelecer a associação entre os níveis de Endocan-1 e PlGF. A hipótese nula foi rejeitada quando p <0,05. 
Resultados: O grupo de pacientes foi composto por normotensas (n = 67) e pacientes com PE (n = 50). Uma 
correlação negativa entre Endocan-1 e PlGF foi observada em todo o grupo de pacientes (r = -0,605; p <0,001); bem 
como no grupo PE (r = -0,545; p <0,001). 
Conclusão: Os níveis de endocan-1 estão aumentados em pacientes com PE e inversamente correlacionados com 
os níveis de PlGF. Sugerimos a importância de analisar moléculas angiogênicas e pró-inflamatórias 
concomitantemente em mulheres com PE para melhor compreender a fisiopatologia da doença. Ambas as moléculas 
são concorrentes fortes como biomarcadores de PE e o trabalhos futuros poderão avaliar quaisquer mecanismos que 





Preeclampsia (PE) is one of the three major causes of maternal morbidity and mortality in the world, 
affecting 2% to 8% of all pregnancies.1 The etiology of PE remains unknown, but is thought to begin in 
placentation, when there is impairment in the vascular remodeling of the uterine spiral arteries leading to a 
decrease in perfusion and high uteroplacental resistance, creating an environment of hypoxia to placental 
and fetal tissues. Placental hypoxia results in the release of cytokines that when exposed to maternal 
circulation change the vascular response leading to widespread dysfunction of the maternal endothelium.2-7 
Identifying a patient with PE is one of the major goals of prenatal care in order to refer the patient to 
high-risk pregnancy protocols, with specific treatment, and if necessary, plan the termination of pregnancy8. 
The Endocan-1 molecule is a soluble proteoglycan expressed specifically in endothelial cells. This 
molecule has been studied in experimental models as well as in vivo and has been proved as a possible 
marker and predictor of many diseases9-11 associated with the vascular endothelium.9,12-21 Therefore, 
Endocan-1 appears to play a key role in tumor progression as well as in the regulation of the inflammatory 
process.22 
Regarding the association of Endocan-1 with PE, our group recently published a study that 
demonstrated a significant increase of Endocan-1 levels in maternal plasma, in women with 
preeclampsia,23 subsequently Chang et al., demonstrated the same association in placental tissue.24 and 
Cakmak et al., associated  higher serum endocan concentrations with the severity of the disease.25 
A molecule that has been widely associated with the pathophysiology of diseases is placental 
growth factor (PlGF). It is produced by the placenta and has angiogenic action. During pregnancy PlGF is 
considered a marker of placental dysfunction. Plasma concentrations of PlGF are down-regulated in 
patients with PE and intrauterine growth restriction (IUGR), and it has been studied as a biomarker and risk 
predictor of developing PE.6, 26, 27 
To predict the chances of developing preeclampsia, it is important to associate molecules that are 
related to both cell growth and inflammatory cytokines, two key points of PE patients. We hypothesized that 
would be a negative correlation between Endocan-1 and PlGF. Thus objective of this study was to correlate 
the values of Endocan-1 and PlGF in the plasma of pregnant women with and without PE. 
 
Methods 
Observational, case-control study that included pregnant women with single fetus and with or without 
diagnosis of PE, who were hospitalized in São Lucas Hospital, Pontifical Catholic University of Rio Grande 
do Sul (HSL/PUCRS), Porto Alegre, Brazil, between 2010 and 2013. All samples were collected after 
obtaining informed, written consent. The study was approved by the institution Scientific and Ethics 
Research Committee (No. 11/05352-CEP). Preeclampsia for research was defined according to the 
National High Blood Pressure Education Program28 and to the VI Brazilian Guidelines on Hypertension 
2010.29 blood pressure ⩾140/90 mmHg, associated with pathological proteinuria ⩾300 mg/24h or 
proteinuria/creatininuria ratio ⩾0.3, after 20 weeks of gestation. The early onset PE was considered when 
PE developed with GA < 34 weeks. The PE group was called “PE pure” when pregnant women with 
superimposed PE and HELLP syndrome (Hemolysis, Elevated Liver Enzymes, Low platelet Count) were 
excluded from analysis. 
Data from maternal identification, physical examination (at hospital admission), previous medical 
history, maternal family history, laboratory tests, delivery, and the newborn were recorded. For both groups 
women were excluded if they had a previous diagnosis of kidney disease, liver disease, active infection, 
multiple gestation and/or lack of information in the database.  
 
Sample collection 
Maternal blood collection was performed after diagnosis (PE group) and hospitalization for delivery 
(normotensives – NT), in the third trimester of pregnancy. A total of 117 patients were collected (50 with PE 
and 67 - NT). Before delivery, 4 ml of maternal blood was collected in ethylenediamine tetraacetic acid 
(EDTA) tubes. The samples were processed in the Nephrology Laboratory - HSL/PUCRS, and centrifuged 
at 2000 g for 10 min, stored in a 600 μl aliquots firstly, at −20ºC and then at −80°C until the time of analysis. 
Laboratory exams to evaluate the severity of PE were conducted only in pregnant women with PE. 
 
Sample preparation  
Samples were prepared according to instructions of the Milliplex assay kit – MagPlexTH-C assay supplier. 
In order to calculate the concentration of molecules, MagPlexTH-System C – microspheres assay 
(MAGPIX® System, Luminex, Austin, Texas, USA) kit milliplex HADK2MAG-61K-05 and HCVD1MAG-67K-
02 (Millipore Corporation, Billerica, MA, USA) and Exponent software (Xponent 4.2) were used. The intra-
assay and inter-assay coefficient of variation was <10%. The linear correlation coefficient (r) of Endocan-1 
standard curve, according to the Luminex instrument, was r = 0.98 and of PlGF r = 0.99. 
 
Statistical analysis 
Statistical tests were conducted using the Statistical Package for Social Sciences version 19 (SPSS 
19.0) for Windows, Graphpad Prism 6 and WINPEPI (PEPI-for-windows). Quantitative variables were 
presented as mean ± standard deviation (SD) or median and interquartile range (IQR) as appropriate, 
Mann–Whitney U-test and Student t test were used depending on the data distribution. For categorical 
variables, we used percentage and applied the Chi-square test or Fisher's exact test. Correlations between 
parameters were tested with Pearson's correlation coefficient. Data related to the dosage of Endocan-1 and 
PlGF were analyzed from the logarithmic transformation by Analysis of Covariance (ANCOVA) adjusted for 
BMI, gestational age (GA), and maternal age (presented as geometric mean). To estimate the proportional 
difference of cytokines between groups, the mean ratio (MR) and confidence interval of 95% were 
calculated. The magnitude of difference was estimated by Cohen effect size. The null hypothesis was 




Clinical and demographic characteristics, physical examination data, laboratory tests and data at the time 
of delivery are presented in table 1. Physical examination data are relative to the day of admission at 
HSL/PUCRS. 
For clinical data we opted to use de delivery GA data in order to use the same period of time in both 
groups. At the diagnosis of PE, 21 were preterm (10 with GA <  34 weeks) and 20 patients were diagnosed 




Table 1. Socio-demographic data and maternal and perinatal outcomes from NT and PE groups 
Parameters NT (67) PE (50) p-value 
Maternal age, years 26±5 26±6.8 0.10 
White, n (%) 34 (52) 31 (65) 0.25 
Primiparous, n (%) 28 (42) 25 (51) 0.35 
Chronic hypertension, n (%) 0 (0) 12 (24.5) - 
Previous PE, n (%) 1 (1.5) 12 (24.0) - 
BMI, kg/m2(weight at end of 
pregnancy) 
30.4±5.8 32.3±5.4 0.081 
SBP, mmHg 119±10 157±17 <0.001* 
DBP, mmHg 75±8 101±14 <0.001* 
GA at delivery, weeks 39.6±1.4 36.7±3.7 <0.001* 
Cesarean section, n (%) 22 (32.8) 38 (76.0) <0.001* 
5-minute Apgar, n** 9.4 ±0.6 8.72±1.21 <0.001* 
Birth weight, Kg 3,393±458 2,789±904 <0.001* 
Placental weight, Kg 649±142 590±179 0.063 
Hematocrit, % 35.2±2.5 36.22±3.51 0.14 
Hemoglobin, g/dL 11.6±0.9 12.31±1.28 0.004* 
Platelets, mm³ (mil)  211.00±59.05 - 
Creatinine, mg/dL  0.81±0.21 - 
Proteinuria, P/C rate  0.67 [0.42;2.2] - 
Fasting glucose, mg/dL 75.2±9.3 78.9±13.7 0.26 
NT - Normotensive pregnancy; PE – Preeclampsia; GA - Gestational age; BMI - Body Mass Index; SBP -Systolic blood pressure; 
DBP - diastolic blood pressure (at admission); Data are presented as mean ± SD (Student's t-test), or absolute numbers and 
percentage (Fisher's exact test), as appropriate. *p <0.05 between NP and PE.  ** In control group, non-newborn received Apgar 
<7; and in PE group, 2 patients received Apgar <7.  (Table is based on a previous published study23). 
 
Analysis of study molecules  
The mean levels of PlGF in NT and PE pure was 58.4 pg/mL versus 33.05 pg/mL and in Endocan-1 was 
2032.6 pg/mL versus 3357.8 pg/mL, respectively. For statistical analysis the logarithmic transformation was 
made and ANCOVA test was applied. Lower levels of PlGF were found in the PE pure group (MR= 0.38; 
95% CI: 0.15–0.95; p= 0.041), (Cohen’s D= 0.54) and higher levels of Endocan-1 were found in maternal 
plasma in PE pure group (MR=1.56; 95% CI: 1.22 - 2,01, p=0.001) with a moderate effect size (Cohen’s D= 
0.93) - Recently published by our group23. 
When PE group was divided into early PE (< 34 weeks; ≥ 34 weeks and controls), we found in early 
PE lower levels of PlGF (p=0,009) and higher levels of Endocan-1 (p<0,001).  
Finally, a negative correlation between Endocan-1 and PlGF was noted in the entire group (r= -
0,605; p< 0.001); as well as in the PE group (r= -0,545; p< 0.001) (Figure 1). 
 
Discussion 
PlGF was approximately 60% lower in patients with PE pure as compared to the control group. In contrast, 
the level of Endocan-1 between the two groups was 56% higher in patients with PE pure, and it was seen a 
strong negative correlation between the two molecules. The early PE group also showed its importance in 
molecular analysis, when early PE presented a statistically lower level of PlGF and higher level of 
Endocan-1. It could suggest both molecules as biomarker of early onset PE. 
Many factors that may be related to PE has been proposed, but the most prominent have been 
associated with protein receptors of the VEGF family, particularly sVEGFR1 (soluble vascular endothelial 
growth factor receptor-1), PlGF, and VEGF (vascular endothelial growth factor).30,31 
The circulating PlGF in human beings is predominantly PlGF-1 (currently there are PlGF 1 to 4), 
mainly produced by the placenta, significantly reduced in PE,32,33 due to a negative regulation that occurs 
under hypoxia,34 even before the onset of PE symptoms.30 However, the role of PIGF in the pathogenesis of 
PE is not entirely known, partly because its physiologic action is not fully understood. In 2008, however, 
Osol, et al., demonstrated PlGF-1 as a potent vasodilator particularly on uterine arteries, mediated specially 
by the release of nitric oxide in pregnancy that could also regulates the venous tone. In the presence of 
higher levels of sVEGFR-1, PlGF is down regulated, which could diminish the vasodilation process and 
lead to hypertension, seen in patients with PE.35 
Since early pregnancy cell injury occurs in the extracellular matrix and in the vessel walls of the 
maternal decidua to create a propitious environment for embryo implantation. Ischemic lesions in the 
placenta resulting from a poor remodeling of decidual vessels release molecular mediators in the maternal 
circulation, creating an imbalance between vasoconstrictors and vasodilators, culminating in PE syndrome 
with a progressing systemic response. However, it is thought that in normal pregnancy the 
syncytiotrophoblast self-renews leaving apoptotic debris in the maternal circulation, what leads to an 
expected inflammatory response during placental growth.  
The significant increase in Endocan-1 concentration seen in maternal plasma might be due to this 
intense response to this process of physiological development, together with the increased release of 
proinflammatory cytokines already observed in previous studies.7 
Is questioned which molecule(s) would be mediating the inverse correlation found between PlGF 
and Endocan-1 and which one seems to firstly change in the pathophysiology of the disease. There is a 
lack of studies to answer this question clearly. Its known that studies that evaluated both molecules in the 
first trimester of pregnancy, in separate, showed that both Endocan-1 and PlGF are decreased in patients 
who developed PE.36 Findings from our group demonstrated that PlGF remains down-regulated, but 
Endocan-1 is tends to increase throughout gestation. This occurs, in part, due to the ischemia that begins 
and compromises maternal circulation. 
All of patients of our study were included in the third trimester of gestation and the level of cytokines 
was adjusted for gestational age, to minimize the influence of this confounding factor in the results. 
PlGF is a placental growth factor and the placenta plays a crucial role in fetal nutrition. Endocan-1, a 
cytokine of predominantly inflammatory nature, injures the vasculature and therefore contributes to the 
reduction of placental flow, IUGR, and low placental weight. 
To our knowledge, there are no complete articles in the literature that correlate these two molecules 
in PE. 
Therefore, the study contributed to previous findings by demonstrating decreased PlGF and 
increased Endocan-1 in the third trimester of pregnancy in PE and its importance in early onset disease. 
We believe that, in addition to PlGF, promising molecule in studies involving PE, Endocan-1 also seems to 
play a role in the PE pathogenesis and would be related with some clinical findings of the disease, but 
future researches should be done to clarify these hypotheses. 
 
Conclusion 
This study evaluated the presence of Endocan-1 and PlGF molecules in maternal plasma; it also correlated 
the levels of this cytokine in patients with PE and NT. In patients with PE, Endocan-1 was significantly 
increased and PlGF decreased in maternal plasma. The role of this cytokines in the preeclampsia 
pathophysiology needs to be continuously studied. 
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Figure 1. Correlation between Endocan-1 and PlGF 
A) Correlation between Endocan-1 and PlGF in the entire group  
B) Correlation between Endocan-1 and PlGF PE group  
 
  
